Introduction: Hepatoepithelioid hemangioendothelioma (HEHE) is a rare, low-grade malignant vascular tumor that can occur in multiple parts of the body but primarily affects the liver. It is marked by the presence of endothelial cells showing characteristics of both vascular and epithelial cells. The tumor typically appears as a vascularized tumor, displaying different levels of abnormal cell features. Despite developing and improving diagnostic methods, misdiagnosis remains a challenge due to its overlapping features with other tumors which primarily affect the liver. Aim of Study: This review aims to summarize current knowledge on the clinical and radiological manifestations, diagnostic challenges, and treatment managements of HEHE with a focus on surgical therapies and possible signs of recurrence. Materials and Methods: A comprehensive review of the literature on hepatoepithelioid hemangioendothelioma was performed using the PubMed database. Results and Conclusions: Hepatoepithelioid hemangioendothelioma progression is unpredictable, as both benign and malignant variants can occur. Due to its rarity and variability in both clinical and radiological presentation, accurate diagnosis of this tumor is challenging for clinicians. Currently, there is no universally accepted standard treatment protocol as a consequence of low prevalence of HEHE. Despite this, liver transplantation remains a therapeutic management of choice, particularly for patients with widespread or non-resectable disease. Nonetheless, long-term management is essential, involving regular monitoring, imaging studies, and liver function assessments to detect any signs of recurrence or emerging complications. More large-scale, long-term studies are needed to optimize management strategies for HEHE.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is one of themost common chronic liver diseases worldwide and is strongly linked to obesity and type 2diabetes mellitus. Glucagon-like peptide-1 (GLP-1) receptor agonists have gained attentionbecause of their hepatoprotective and cardiometabolic effects.Aim: This narrative review summarizes current evidence on GLP-1 receptor agonists in thetreatment of MASLD and metabolic dysfunction-associated steatohepatitis (MASH).Materials and methods: A literature review was conducted using PubMed, Scopus and GoogleScholar. Included studies comprised clinical trials, randomized controlled trials, meta-analyses,review articles and international guidelines published between 2021 and 2025.Results: Evidence suggests that GLP-1 receptor agonists, especially semaglutide andliraglutide, reduce hepatic steatosis, insulin resistance, body weight and inflammatory activityin patients with MASLD or MASH. Several studies demonstrated improvements in liverhistology and non-invasive fibrosis markers, although antifibrotic effects were less consistentin advanced cirrhosis. These agents also improved glycemic control and cardiovascular riskfactors, with an acceptable safety profile.Conclusions: GLP-1 receptor agonists appear to be a promising therapeutic option for MASLDand MASH. However, further long-term randomized studies are required to confirm theireffects on fibrosis and liver-related outcomes.
7 September 2026 in International Journal of Innovative Technologies in Social Science
Background and Objectives. To synthesize contemporary clinical evidence on rheumatoid cervical spine instability, identify predictors of structural progression, and distinguish the threshold for neurosurgical referral from the threshold for operative intervention. Materials and Methods. A focused narrative clinical review was based on a PubMed/MEDLINE search updated through August 2026. Original clinical studies addressing cervical involvement, imaging, longitudinal progression, predictors, neurological consequences, and surgical outcomes were prioritized. Forty clinical publications formed the principal evidence base, no meta-analysis or formal risk-of-bias grading was performed. Results. Modern disease-modifying antirheumatic therapy appears to reduce some de novo cervical lesions, but established instability may continue to progress. Pre-existing cervical abnormalities, destructive peripheral disease, longer rheumatoid arthritis duration, seropositivity, glucocorticoid exposure, osteoporosis, and previous joint surgery are associated with cervical involvement or progression. Serial imaging is particularly important because mechanical deterioration may precede overt neurological compromise. Conclusions. Assessment should integrate rheumatological phenotype, established structural disease, longitudinal mechanical progression, and neural consequences. Neurologically intact patients with documented structural progression represent a clinically important intermediate group in whom earlier spine or neurosurgical assessment may be considered without implying prophylactic surgery.
30 June 2026 in International Journal of Innovative Technologies in Social Science
Pneumocystis jirovecii pneumonia (PJP) remains a clinically significant opportunistic infection in solid organ transplant (SOT) recipients despite advances in prophylaxis, diagnostics, and treatment. This review aims to summarize current knowledge regarding epidemiology, risk factors, diagnosis, treatment, and prevention of PJP in this population, with particular emphasis on evolving concepts of risk stratification. Although universal trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis has significantly reduced incidence, breakthrough and late-onset infections continue to occur, particularly in the context of fluctuating immunosuppression. The risk of PJP is primarily determined by the net state of immunosuppression rather than time since transplantation alone. Key risk factors include lymphopenia, cytomegalovirus infection or reactivation, treatment of acute rejection with high-dose corticosteroids or lymphocyte-depleting agents, hypogammaglobulinemia, and advanced age. Clinically, PJP in SOT recipients is often acute and rapidly progressive, frequently leading to severe hypoxemic respiratory failure and higher mortality compared with HIV-associated disease. Diagnosis requires integration of clinical findings, high-resolution computed tomography, and microbiological analysis of bronchoalveolar lavage. Molecular assays improve sensitivity, but differentiation between active infection and colonization remains challenging. Serum (1→3)-β-D-glucan may support diagnosis but lacks specificity. Trimethoprim-sulfamethoxazole remains first-line therapy and prophylaxis, while alternative agents are less effective. Emerging molecular and immunological tools may improve risk stratification and guide individualized prophylaxis strategies.
30 June 2026 in International Journal of Innovative Technologies in Social Science
Introduction: Epithelioid hemangioendothelioma (EHE) is a rare vascular tumor of low-to-intermediate malignant potential with an incompletely defined biological behaviour, exhibiting both benign and malignant features. It most commonly affects the liver, but may also involve other organs, such as the lungs and bones. Due to its heterogeneous clinical presentation and similarity to other vascular tumors primarily affecting the liver, misdiagnosis remains a common clinical challenge. Currently, several therapeutic approaches are used depending on various factors, but liver transplantation (LTx) is increasingly considered as the treatment option for patients with metastatic HEHE, particularly in unresectable cases. Several studies indicate a favorable prognosis following transplantation for HEHE. Aim of the Study: The aim of this study is to review the existing literature on treatment outcomes and to identify prognostic factors in patients undergoing LTx due to HEHE. Materials and Methods: A comprehensive literature review was performed using the PubMed database. Results and Conclusions: LTx is a crucial treatment option for patients with unresectable and multifocal HEHE. Current data indicate that post-transplant survival rates are favorable, with the potential to achieve durable, recurrence-free survival - even in the presence of extrahepatic metastases. Several prognostic factors have been identified that may influence post-transplant outcomes, including tumor burden, presence of extrahepatic disease (EHD), vascular invasion and tumor growth dynamics. In light of the limited efficacy of available systemic therapies, LTx should be considered the preferred treatment option in carefully selected patients with advanced HEHE. Nevertheless, long-term follow-up remains crucial to identify potential recurrence or complications.